+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
M

Actively Recruiting

Researchers are evaluating the effectiveness of minimally invasive extracorporeal circulation MiECC compared to conventional cardiopulmonary bypass cCPB in reducing serious complications after cardiac surgery. This large multicenter randomized controlled trial, led by the Aristotle University of Thessaloniki, focuses on patients undergoing coronary artery bypass grafting, aortic valve replacement, or both, aiming to see if MiECC can lower the rate of serious postoperative problems such as death, heart attack, stroke, kidney injury, and respiratory complications within 30 days after surgery. Participants are assigned to receive cardiac surgery using either a MiECC system or a conventional heart-lung machine cCPB. The study includes patients undergoing elective or urgent surgery without circulatory arrest and excludes those needing emergency operations or major aortic surgery. The trial will recruit about 1,300 participants across 10 to 15 centers worldwide to detect meaningful differences in postoperative outcomes. During the study, participants will be monitored for serious adverse events up to 30 days after surgery. Researchers will also track blood transfusions, time spent in the cardiac intensive care unit and hospital, new onset postoperative atrial fibrillation, delirium, and health-related quality of life up to 90 days after surgery. Safety and recovery will be carefully assessed through hospital records and clinical evaluations throughout the initial hospital stay and follow-up periods.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
13 locations
P

Actively Recruiting

Researchers are conducting a prospective observational study to follow participants with non-idiopathic pulmonary fibrosis and other fibrosing interstitial lung diseases ILD over 24 months. The main goal is to improve classification of progressive pulmonary fibrosis PPF and establish how often it occurs in key ILD subtypes such as connective tissue disease-associated ILD, fibrotic hypersensitivity pneumonitis, and non-IPF idiopathic interstitial pneumonia. The study also aims to validate a new PPF classifier and compare its prediction performance with multi-dimensional approaches. Participants with fibrosing ILD will not receive any investigational therapy but will be extensively evaluated through clinical, physiological, and imaging assessments. After confirming eligibility, participants will undergo scheduled follow-up visits over two years during which clinical data and blood samples will be collected at specific times. The study focuses on observing disease progression and validating biomarkers without prescribing treatments. Throughout the study, participants will have clinical evaluations including pulmonary function tests and imaging. Researchers will measure transplant-free survival over 12 months following an initial observation year, focusing on lung function decline and biomarker performance. Safety and health will be monitored, and participants usual care will continue alongside study assessments. The total duration of participation is 24 months.

Age: 18Years - 80YearsAll Genders
24 locations
P

Actively Recruiting

Researchers are studying inhaled treprostinil to assess its safety and effectiveness in people with progressive pulmonary fibrosis PPF. This Phase 3, multinational, randomized, double-blind, placebo-controlled trial will compare inhaled treprostinil to a placebo over one year. The study focuses on adults diagnosed with PPF who have shown lung fibrosis progression despite standard treatments. Participants will be randomly assigned to receive either inhaled treprostinil or a matching placebo using an ultrasonic nebulizer four times a day. The dose starts at 3 breaths per session and will be gradually increased to a target of 12 breaths per session or the highest tolerated dose. The treatment period includes six visits at weeks 4, 8, 16, 28, 40, and 52. Those completing the 52-week treatment may join an open-label extension study. During the study, participants will undergo lung function tests like forced vital capacity FVC and lung diffusion capacity DLCO, complete questionnaires about their lung disease, and have blood tests to measure biomarkers. Researchers will monitor safety by tracking adverse events, vital signs, lab results, and electrocardiograms. The main measure is the change in lung function from the start to week 52, with additional assessments of clinical worsening, acute lung exacerbations, survival, and oxygen use.

Age: 18Years +All GendersPhase 3
165 locations